New Insights into the Management of Giant Cell Arteritis
Race May Not Be a Risk Factor for Giant Cell Arteritis
Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality
New Recommendations Guide Imaging in Large-Vessel Vasculitis
Tocilizumab Is Effective to Treat GCA
FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis
How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
GCA Relapse Possible When Discontinuing Tocilizumab
